{"nctId":"NCT00654927","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","startDateStruct":{"date":"2003-11"},"conditions":["Multiple Sclerosis"],"count":177,"armGroups":[],"interventions":[{"name":"Fampridine-SR b.i.d. (Twice Daily)","otherNames":["4-aminopyridine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject must have been previously enrolled in an Acorda Therapeutics or an Elan Corporation sponsored study for multiple sclerosis and received either Fampridine or placebo.\n* The subject must have multiple sclerosis as determined by the Principal Investigator.\n* The subject, male or female, must be at least 18 years of age. Any subject who is now over the age of 70 must be in good overall health in the judgment of the Investigator.\n* The subject must be of adequate cognitive function, as judged by the Investigator.\n* Any subject who is female and of childbearing potential, regardless of sexual activity, must have a negative urine pregnancy test at the Screening Visit.\n\nExclusion Criteria:\n\n* The subject is a female who is either pregnant or breastfeeding, or of child-bearing potential, who, if engaged in active heterosexual relations and has not had a hysterectomy or bilateral oophorectomy, would not use one of the following birth control methods: tubal ligation, implantable contraception device, oral, injectable or transdermal contraceptive, barrier method or sexual activity restricted to vasectomized partner.\n* The subject withdrew from a previous Fampridine study because of a Serious Adverse Event that was possibly, probably or definitely related to Fampridine.\n* The subject has a history of seizures or has evidence of past, or possible, epileptiform activity on an EEG.\n* The subject has either a clinically significant abnormal ECG or laboratory value(s) at the Screening Visit, as judged by the Investigator\n* The subject has angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator.\n* The subject has a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine tablet\n* The subject has received an investigational drug, except for Fampridine- SR (or matching placebo) under Protocol MS-F202, within 30 days prior to the Screening Visit; or the subject is scheduled to enroll in an investigational drug trial at any time during this study.\n* The subject has received compounded 4-aminopyridine (4-AP) within 14 days of the Screening Visit.\n* The subject has had an onset of an MS exacerbation within 30 days prior to the Screening Visit, or, if in the judgment of the Investigator, has not stabilized from a prior exacerbation episode.\n* The subject has started on a concomitant medication regimen for an underlying disease/symptom within the past 7 days; or has started an interferon or chemotherapeutic agent for multiple sclerosis within the past 4 weeks.\n* The subject has a history of drug or alcohol abuse within the past year.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Treatment Emergent Adverse Events (TEAE).","description":"All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":"99.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":"36.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":"41.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":"15.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":"38.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"47.5"}]}]}]},{"type":"SECONDARY","title":"Timed 25 Foot Walk (T25FW)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Subject Global Impression (SGI)","description":"The patient was asked to complete a Subject Global Impression (SGI) questionnaire at Visit 1 and every study visit thereafter except the Follow-up visit. This questionnaire asked the patient to rate the effects of the investigational drug on his/her physical well-being during the preceding week, using a 1 to 7 point scale (1 = terrible, 7 = delighted)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.79","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.42","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.73","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.10","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":"1.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.28","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.08","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Clinician Global Impression of Change (CGIC)","description":"The CGIC was based on the Investigator's overall impression of the patient's neurological status and general state of health related to his or her participation in the study, specifically in regard to signs and symptoms associated with MS. Neurological status was rated according to a 1 to 7 point scale (1 = very much improved, 7 = very much worse)","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.83","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.76","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.96","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.87","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.29","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":"1.75"}]}]}]},{"type":"SECONDARY","title":"Expanded Disability Status Scale (EDSS)","description":"Based on the baseline neurological exam, each patient was scored according to the Expanded Disability Status Scale, which rates disability on a 0 to 10 scale (0 = normal neurologic examination, 10 = death)\n\n\\*EDSS assessments were not well synchronized to study period because of wide differences in interval between screening and initiation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.26","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.03","spread":"1.31"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":177},"commonTop":["Urinary Tract Infection","Fall","Insomnia","Muscular Weakness","Multiple Sclerosis Relapse"]}}}